Parameters (n = 43)		Number (%) or median (min-max)
Age (year)		56	(25-73)
Gender (Female/Male)		14/29
Disease	Multiple Myeloma	26	(60,4)
	Hodgkin Lymphoma	4	(9,4)
	Non-Hodgkin Lymphoma	13	(30,2)
Pre-transplant chemotherapy line	≤3	37	(86)
	>3	6	(14)
Pre-transplant response to therapy	Complete remission	35	(81,3)
	Partial remission	7	(16,2)
	Stabil disease	1	(2,5)
CMV status pre-transplant	CMV IgG positive	43	(100)
	CMV IgM positive	0	(0)
Engraftment time (day)	Neutrophil count	12	(9-51)
	>500/mm3	14	(8-51)
CMV reactivation in the study cohort	Platelet count > 20000/mm3	43	(11,9)
	Yes	317	(88,1)
	No
Reason for checking CMV level	Prolonged fever	14	(32,5)
	Diarrhea	5	(11,6)
	Pneumonia	9	(20,9)
	Liver enzyme elevation	6	(14,1)
	Cytopenia	9	(20,9)
Time to reactivation (day)		39	(8-1825)
CMV antigenemia (IU/mL)	Moment of diagnosis	467	(27-36385)
	Peak level	482	(27-78987)
Anti-CMV therapy	Ganciclovir	12	(57,1)
	Valganciclovir	9	(42,9)
Treatment-related toxicity	Neutropenia	2	(20)
	Pancytopenia	2	(20)
	Hypomagnesemia	3	(30)
	Hypocalcemia	2	(20)
	Acute kidney failure	1	(10)
Anti-CMV therapy (day)	Induction therapy	14	(7-28)
	Maintenance therapy	14	(7-32)
Development of CMV disease	Yes	6	(13,9)
	No	37	(86,1)
Mortality (%)	100-day	6,9
	Overall	46,5